Trwa ładowanie...
Notowania

SPH Sales revenues for October 2022

“Sopharma” AD (the Company) notifies that for October 2022 the Company recorded a increase in sales of 30% compared to the same month of the previous year, incl. 13% decrease in domestic sales and 58% increase in export sales.
For the ten months since the beginning of the year the revenues from sales of products increase by 19%, incl. 12% increase of sales for the domestic market and 23% increase in export sales.

Załączniki

Inne komunikaty

DataTytułKursZmiana
2024-09-19
SPH Notification from Donev Investments Holding AD in accordance with Regulation 596/2014 for transactions with shares of Sopharma AD
12,65
0,00
2024-09-18
SPH Notification from Donev Investments Holding AD in accordance with Regulation 596/2014 for transactions with shares of Sopharma AD
13,00
-2,69
2024-09-17
SPH Notification from Donev Investments Holding AD in accordance with Regulation 596/2014 for transactions with shares of Sopharma AD
13,00
0,00
2024-09-16
SPH Notification from Donev Investments Holding AD in accordance with Regulation 596/2014 for transactions with shares of Sopharma AD
13,00
0,00
2024-09-13
SPH Notification from Donev Investments Holding AD in accordance with Regulation 596/2014 for transactions with shares of Sopharma AD
13,20
-4,17
2024-09-12
SPH Notification from Donev Investments Holding AD in accordance with Regulation 596/2014 for transactions with shares of Sopharma AD
14,40
-8,33
2024-09-11
SPH Notification from Donev Investments Holding AD in accordance with Regulation 596/2014 for transactions with shares of Sopharma AD
14,40
0,00
2024-09-10
SPH Notification from Donev Investments Holding AD in accordance with Regulation 596/2014 for transactions with shares of Sopharma AD
14,40
0,00
2024-09-10
SPH Notification from Rositsa Doneva in accordance with Regulation 596/2014 for transactions with shares of Sopharma AD
14,40
0,00
2024-09-09
SPH Notification from Donev Investments Holding AD in accordance with Regulation 596/2014 for transactions with shares of Sopharma AD
14,40
0,00